Lung cancer

R2810-ONC-2268

A RANDOMIZED PHASE 2 PLATFORM STUDY TO EVALUATE;CEMIPLIMAB PLUS CHEMOTHERAPY VERSUS CEMIPLIMAB PLUS;CHEMOTHERAPY PLUS OTHER CANCER TREATMENTS FOR THE;PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE;NON-SMALL CELL LUNG CANCER;SUBPROTOCOL 1: REGN7075

Open at Paris since : 12/03/2025
Target : Adult
Phase : Phase II

Trial description

Evaluate the efficacy and safety of the therapeutic combination: ;- Cemiplimab + chemotherapy compared to ;- Cemiplimab + chemotherapy + other anticancer treatments ;for the perioperative treatment of patients with resectable non-small cell lung cancer (NSCLC). ;Efficacy could be assessed in terms of progression-free survival (PFS), complete response rate (CR), or overall survival (OS), as defined in the protocol.

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact